NCT00056381View on ClinicalTrials.gov

Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

June 30, 2004

Conditions

Neutropenia

Interventions

DRUG

Anidulafungin

Trial Locations (1)

19406

Versicor, King of Prussia

Sponsors

Lead Sponsor

Collaborators (1)

Vicuron Pharmaceuticals

All Listed Sponsors

collaborator

Vicuron Pharmaceuticals

INDUSTRY

lead

Pfizer

INDUSTRY

NCT00056381 - Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17 | Biotech Hunter | Biotech Hunter